Shots:

• The US FDA has granted FT designation to Chi-Med’s surufatinib for the treatment of both advanced and progressive pancreatic NET and non-pancreatic NET in patients who are not amenable for surgery
• Based on two P-III studies and ongoing P-Ib study- the company is planning for regulatory interactions in the US- EU and Japan. In Nov’2019- NMPA has accepted the NDA for the therapy to treat non-pancreatic NET and granted PR designation in Dec’2019
• Surufatinib is a novel- oral angio-immuno kinase inhibitor act by inhibiting the tyrosine kinase activity associated with VEGFR and FGFR and has received FDA’s ODD for pancreatic NET in Nov’2019

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Chi-Med